Trial Profile
An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; INO 5401 (Primary) ; INO 9012 (Primary)
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- Sponsors Inovio Pharmaceuticals
- 07 Oct 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 07 Oct 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 11 Jul 2022 Planned End Date changed from 30 Jun 2022 to 31 Dec 2022.